I am a
Home I AM A Search Login

Papers of the Week

Papers: 29 Jan 2022 - 4 Feb 2022

Human Studies

2022 Jan 31

Eur J Neurol

Predictors of Sustained Response and Effects of Anti-CGRP Antibodies Discontinuation and Reinitiation in Resistant Chronic Migraine.


Iannone L F, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F
Eur J Neurol. 2022 Jan 31.
PMID: 35098620.


Guidelines for migraine prophylaxis suggest stopping medication after 6-12 months to reevaluate treatment appropriateness. The Italian Medicines Agency (AIFA) set a mandatory regulation to stop anti-CGRP (calcitonin gene related protein) pathway monoclonal antibody (anti-CGRP mAbs) treatments for 3 months after 12-months of treatment. Herein, we assess the effects of discontinuation and retreatment of anti-CGRP mAbs in resistant chronic migraine patients, evaluating predictive factors of sustained response.